NEW YORK--(BUSINESS WIRE)--Onco360, one of the nation’s largest independent providers of Oncology Pharmacy services, today announced that it has been selected as a limited distribution pharmacy network participant by Pfizer Inc. (“Pfizer”), and can immediately begin dispensing Bosulif® (bosutinib), Inlyta® (axitinib), Sutent® (sunitinib), and Xalkori® (crizotinib). With the addition of these four medications, Onco360’s industry-leading oncology medication portfolio now comprises nearly 40 limited distribution products.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
